What the recent move in STAAR Surgical means for investors

STAAR Surgical (STAA) has attracted fresh attention after a strong month, with the stock returning about 43% and roughly 20% over the past 3 months, prompting investors to reassess the eye lens maker’s current pricing.

That sharp 43.2% 1 month share price return sits alongside a 6.3% year to date share price gain. The 1 year total shareholder return of 51.7% contrasts with weak 3 and 5 year total returns, which suggests momentum is rebuilding after a tough longer stretch.

If STAAR Surgical’s recent rebound has you thinking about where else strong trends might emerge next, it could be worth scanning 37 healthcare AI stocks.

With STAA now trading around $25.08, close to an internal intrinsic value estimate and above the average analyst target of $21.11, the question becomes whether there is still a buying opportunity here or whether the market is already pricing in future growth.

Most Popular Narrative: 6% Undervalued

At a last close of $25.08 against a narrative fair value of $26.56, the current price sits slightly below what the most followed model suggests.

The fair value estimate has risen slightly, moving from approximately $25.88 to $26.56 per share. This reflects modestly stronger underlying assumptions.

The future P/E multiple has declined meaningfully, from around 132.0x to 118.1x. This suggests less multiple driven upside in the revised valuation framework.

The valuation case focuses on faster growth, margin repair and a rich future earnings multiple. The full narrative explains how these elements connect to reach that fair value estimate.

Result: Fair Value of $26.56 (UNDERVALUED)

However, there is still meaningful risk if China remains weak or distributor issues persist, and if new competitors pressure pricing and slow the pace of STAAR Surgical’s growth ambitions.

Another View: Rich Sales Multiple Raises Questions

The narrative model sees STAAR Surgical as slightly undervalued, but its current P/S of 5.2x looks demanding next to the US Medical Equipment industry at 2.8x, a peer average of 3.7x and a fair ratio of 3.4x. If pricing drifts toward that fair ratio, how comfortable are you with the downside risk on the way there?

Next Steps

With sentiment mixed but interest clearly rising again, this is a good moment to look through the numbers yourself and decide where you stand. To see what investors currently view as the bright spots in the story, review the 2 key rewards.

Looking for more investment ideas?

If STAA has sharpened your interest, do not stop here. Broaden your watchlist with a few focused stock ideas that match different priorities and risk appetites.

• Target potential mispricing by scanning 60 high quality undervalued stocks that combine quality fundamentals with discounted valuations.
• Prioritise resilience and stability by reviewing 71 resilient stocks with low risk scores that score well on financial strength and risk metrics.
• Seek underfollowed opportunities by checking the screener containing 23 high quality undiscovered gems that pair solid numbers with relatively low market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.